Familial Chylomicronemia Syndrome Market Size, Share, Growth, Epidemiology and Forecast to 2036

(Albany, New York) – 17th Sep 2026 – DelveInsight’s latest report, “Familial Chylomicronemia Syndrome Market Insights, Epidemiology and Market Forecast – 2036,” provides a comprehensive assessment of the Familial Chylomicronemia Syndrome (FCS) market across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The report offers an in-depth evaluation of historical and forecasted epidemiology, patient burden, treatment patterns, market dynamics, competitive intelligence, therapy uptake, reimbursement, pricing, unmet needs, and the evolving therapeutic landscape through 2036.

According to DelveInsight, the 7MM reported approximately 2,100 diagnosed prevalent cases of FCS in 2025. The disease is a rare autosomal recessive disorder characterized by extremely elevated triglyceride levels, generally exceeding 1,000 mg/dL, resulting from defective lipoprotein lipase activity or related genetic mutations. The FCS treatment landscape is evolving rapidly with the emergence of RNA-targeted therapies directed against apolipoprotein C-III (apoC-III).

Key Takeaways from the Familial Chylomicronemia Syndrome Market

• Approximately 2,100 diagnosed prevalent cases of FCS were reported across the 7MM in 2025.
• The US accounted for the highest diagnosed prevalent cases, with more than 1,300 cases in 2025.
• Approximately 70% of individuals diagnosed with FCS are male, with a median age of diagnosis of around 9 years.
• The diagnosed burden in the US was higher among the 0–17 years age group than among individuals aged 18 years and above in 2025.
• Japan recorded more diagnosed FCS cases than the UK in 2025.
• More than 90% of patients reported difficulty managing fat intake, while 53% experienced symptoms despite adherence to their diets.
• Current approved systemic therapies include Plozasiran (REDEMPLO), Olezarsen (TRYNGOLZA), and Volanesorsen (WAYLIVRA).
• TRYNGOLZA (olezarsen) became the first treatment approved in the US for adults living with FCS as an adjunct to diet.
• Plozasiran (REDEMPLO), an siRNA therapy targeting apoC-III, received US FDA approval in November 2025.
• Key companies active in the FCS market include Ionis Pharmaceuticals, Swedish Orphan Biovitrum, and Arrowhead Pharmaceuticals.

Keen to know more about the Familial Chylomicronemia Syndrome market? Request a sample copy of the report for detailed market insights, epidemiology, treatment patterns, competitive intelligence, and forecast analysis.

https://www.delveinsight.com/sample-request/familial-chylomicronemia-syndrome-market

Key Factors Driving the Familial Chylomicronemia Syndrome Market

Development of Targeted Therapies

The FCS market is shifting from an approach dominated by strict dietary management toward targeted pharmacological therapies. Antisense oligonucleotides and small interfering RNA (siRNA) therapies targeting apoC-III have introduced new mechanisms for reducing triglyceride levels and improving disease management. The approval of therapies such as Plozasiran has further strengthened the targeted treatment landscape.

High Unmet Clinical Need

FCS is associated with a substantial risk of recurrent acute pancreatitis, which can become life-threatening. Despite advances in treatment, residual pancreatitis risk and incomplete triglyceride control remain important clinical challenges, creating continued demand for effective therapies.

Increasing Adoption of RNA-based Therapies

RNA-based treatments are becoming central to the FCS treatment landscape. Olezarsen and Volanesorsen use antisense oligonucleotide technology to inhibit apoC-III production, while Plozasiran uses siRNA technology to selectively silence hepatic apoC-III production. These mechanisms support sustained triglyceride reduction and provide alternatives to conventional dietary management.

Favorable Regulatory Support for Rare Diseases

Regulatory incentives, including orphan-drug designations and accelerated development pathways, can help reduce development barriers for therapies targeting rare diseases such as FCS. Such regulatory support is contributing to the advancement and commercialization of novel treatment approaches.

Persistent Diagnosis and Disease-Awareness Challenges

Delayed diagnosis and limited disease awareness remain important barriers. Because FCS is rare and its exact prevalence remains difficult to establish, patients may experience delays before receiving a definitive diagnosis. Genetic testing and improved recognition of characteristic clinical and laboratory findings are therefore important components of disease management.

Competitive Landscape

The FCS competitive landscape has evolved significantly with the introduction of targeted apoC-III therapies. Key companies identified by DelveInsight include:

• Ionis Pharmaceuticals
• Swedish Orphan Biovitrum
• Arrowhead Pharmaceuticals

The principal approved therapies include Plozasiran (REDEMPLO) from Arrowhead Pharmaceuticals, Olezarsen (TRYNGOLZA) from Ionis Pharmaceuticals and Swedish Orphan Biovitrum, and Volanesorsen (WAYLIVRA) from Ionis Pharmaceuticals.

The emergence of siRNA technology alongside established antisense oligonucleotide therapies is contributing to greater diversification within the FCS treatment market.

Recent Developments in the Familial Chylomicronemia Syndrome Market

• May 2026: Ionis Pharmaceuticals lowered the price of TRYNGOLZA from USD 595,000 to USD 40,000, representing a 93% reduction, ahead of anticipated label expansion.
• January 2026: Ionis Pharmaceuticals announced that TRYNGOLZA generated USD 105 million in preliminary US net product sales in 2025.
• November 2025: The US FDA approved REDEMPLO (plozasiran) as an adjunct to diet to reduce triglycerides in adults with FCS.
• September 2025: TRYNGOLZA received approval in the European Union as an adjunct to diet for adults with genetically confirmed FCS.
• December 2024: The US FDA approved TRYNGOLZA as an adjunct to diet for triglyceride reduction in adults with FCS, based on data from the Phase III BALANCE study.
• May 2019: Volanesorsen (WAYLIVRA) received conditional marketing authorization from the European Commission as an adjunct to diet in adults with genetically confirmed FCS.

What is Familial Chylomicronemia Syndrome?

Familial Chylomicronemia Syndrome (FCS), also known as lipoprotein lipase (LPL) deficiency, Fredrickson Type 1 Hyperlipoproteinemia, or Type 1 Hyperlipidemia, is a rare genetic lipid disorder characterized by extremely high triglyceride levels. It is most commonly associated with mutations in the LPL gene, although variants in APOA5, APOC2, GPD1, GPIHBP1, and LMF1 can also result in the condition.

FCS commonly manifests during childhood or early adulthood. Clinical symptoms can include failure to thrive, nausea, vomiting, abdominal pain, lipemia retinalis, eruptive xanthomas, and hepatosplenomegaly. The most serious complication is acute pancreatitis, which can be life-threatening.

Diagnosis is based on clinical presentation, laboratory findings, and genetic testing. Extremely elevated fasting triglycerides and characteristic clinical manifestations can prompt evaluation, while genetic testing can confirm mutations associated with FCS and help distinguish the disease from secondary causes of severe hypertriglyceridemia.

Current Treatment Landscape

The primary goal of FCS treatment is to reduce triglyceride levels and prevent recurrent acute pancreatitis. Strict dietary management, particularly a very-low-fat diet and avoidance of alcohol and secondary triggers, remains a cornerstone of disease management.

The pharmacological landscape has expanded through therapies targeting apoC-III:

• Plozasiran (REDEMPLO): An siRNA therapy that selectively silences hepatic apoC-III production. It was approved in the US in 2025.
• Olezarsen (TRYNGOLZA): An antisense oligonucleotide designed to reduce apoC-III production. It was approved in the US in 2024 and subsequently in the EU.
• Volanesorsen (WAYLIVRA): An antisense oligonucleotide targeting apoC-III that received conditional marketing authorization in the EU in 2019.

The treatment paradigm is therefore transitioning toward mechanism-driven therapies that provide sustained triglyceride lowering alongside dietary intervention.

Familial Chylomicronemia Syndrome Epidemiology

DelveInsight’s epidemiology analysis covers the FCS patient population across the seven major markets, including total prevalent cases, diagnosed prevalent cases, gender-specific cases, age-specific cases, and treated cases.

Key epidemiological findings include:

• The 7MM had approximately 2,100 diagnosed prevalent FCS cases in 2025.
• The US had more than 1,300 diagnosed prevalent cases in 2025, the highest among the assessed markets.
• Approximately 70% of diagnosed individuals were male.
• The median age of diagnosis was around 9 years, reflecting the early-onset nature of the disease.
• In the US, diagnosed FCS cases were more concentrated in the 0–17 years age group than in adults in 2025.
• Japan recorded a higher number of diagnosed FCS cases than the UK.
• More than 90% of patients experienced difficulty managing dietary fat intake, and 53% experienced symptoms despite following their diets.

Unmet Needs in Familial Chylomicronemia Syndrome

Despite the introduction of targeted therapies, several unmet needs remain:

1. Residual risk of acute pancreatitis despite treatment
2. Incomplete triglyceride control in some patients
3. Accessibility and high cost of novel therapies
4. Delayed diagnosis and limited disease awareness

These challenges create opportunities for therapies that can provide durable triglyceride control, reduce pancreatitis risk, improve convenience, and broaden access to treatment.

Scope of the Familial Chylomicronemia Syndrome Market Report

• Study Period: 2022–2036
• Historical Period: 2022–2025
• Forecast Period: 2026–2036
• Base Year: 2026
• Geographies: US, Germany, France, Italy, Spain, UK, and Japan
• 7MM Diagnosed Prevalent Cases: Approximately 2,100 in 2025
• US Diagnosed Prevalent Cases: More than 1,300 in 2025
• Epidemiology Segmentation: Total prevalent cases, diagnosed prevalent cases, gender-specific diagnosed prevalent cases, age-specific diagnosed prevalent cases, and treated cases
• Market Segmentation: Region/geographies and drugs/therapies
• Key Companies: Ionis Pharmaceuticals, Swedish Orphan Biovitrum, Arrowhead Pharmaceuticals
• Key Therapies: Plozasiran (REDEMPLO), Olezarsen (TRYNGOLZA), Volanesorsen (WAYLIVRA)
• Analysis: Addressable patient population, market drivers and barriers, cost assumptions and pricing analogues, KOL views, SWOT analysis, reimbursement, conjoint analysis, and unmet needs
• Key Strengths: Epidemiology-based bottom-up forecasting, AI-enabled market research, 11-year forecast, regional market outlook, patient burden trends, treatment addressable market, competitive landscape, company insights, price trends and analogue assessment, therapy adoption/uptake, and peak patient share analysis.

To Know More About the Familial Chylomicronemia Syndrome Market Report

Familial Chylomicronemia Syndrome Market Insight, Epidemiology and Market Forecast – 2036

Table of Contents

1. Report Introduction
2. Executive Summary
3. Key Events
4. Epidemiology and Market Methodology
5. Familial Chylomicronemia Syndrome Market Overview
6. Clinical Landscape Analysis
7. Disease Background and Overview
8. Causes, Signs and Symptoms
9. Diagnosis and Diagnostic Algorithm
10. Treatment and Management
11. Epidemiology and Patient Population
12. Patient Journey
13. Marketed Therapies
14. Competitive Landscape
15. Plozasiran (REDEMPLO)
16. Olezarsen (TRYNGOLZA)
17. Volanesorsen (WAYLIVRA)
18. Market Size and Forecast
19. Drug Uptake and Patient Share
20. Market Access and Reimbursement
21. Pricing and Analogue Assessment
22. KOL and SME Insights
23. SWOT and Conjoint Analysis
24. Market Drivers and Barriers
25. Unmet Needs
26. Market Outlook
27. Company and Therapy Profiles
28. Conclusions and Strategic Insights

About DelveInsight

DelveInsight is a leading market research and consulting firm specializing in the life sciences and healthcare industries. Founded in 2014, the company provides comprehensive market intelligence, epidemiology, and insights across pharmaceuticals, biotechnology, medical devices, and emerging therapies. DelveInsight helps healthcare organizations make informed strategic decisions through data-driven research and industry expertise.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/